Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 313

1.

Absolute proteome quantification of highly purified populations of circulating reticulocytes and mature erythrocytes.

Gautier EF, Leduc M, Cochet S, Bailly K, Lacombe C, Mohandas N, Guillonneau F, El Nemer W, Mayeux P.

Blood Adv. 2018 Oct 23;2(20):2646-2657. doi: 10.1182/bloodadvances.2018023515.

2.

Peptidoglycan potentiates the membrane disrupting effect of the carboxyamidated form of DMS-DA6, a Gram-positive selective antimicrobial peptide isolated from Pachymedusa dacnicolor skin.

Cardon S, Sachon E, Carlier L, Drujon T, Walrant A, Alemán-Navarro E, Martínez-Osorio V, Guianvarc'h D, Sagan S, Fleury Y, Marquant R, Piesse C, Rosenstein Y, Auvynet C, Lacombe C.

PLoS One. 2018 Oct 16;13(10):e0205727. doi: 10.1371/journal.pone.0205727. eCollection 2018.

3.

Finely-tuned regulation of AMP-activated protein kinase (AMPK) is crucial for human adult erythropoiesis.

Ladli M, Richard C, Cantero Aguilar L, Ducamp S, Bondu S, Sujobert P, Tamburini J, Lacombe C, Azar N, Foretz M, Zermati Y, Mayeux P, Viollet B, Verdier F.

Haematologica. 2018 Oct 11. pii: haematol.2018.191403. doi: 10.3324/haematol.2018.191403. [Epub ahead of print]

4.

SNP-array lesions in core binding factor acute myeloid leukemia.

Duployez N, Boudry-Labis E, Roumier C, Boissel N, Petit A, Geffroy S, Helevaut N, Celli-Lebras K, Terré C, Fenneteau O, Cuccuini W, Luquet I, Lapillonne H, Lacombe C, Cornillet P, Ifrah N, Dombret H, Leverger G, Jourdan E, Preudhomme C.

Oncotarget. 2018 Jan 8;9(5):6478-6489. doi: 10.18632/oncotarget.24031. eCollection 2018 Jan 19.

5.

NKp46 expression on NK cells as a prognostic and predictive biomarker for response to allo-SCT in patients with AML.

Chretien AS, Devillier R, Fauriat C, Orlanducci F, Harbi S, Le Roy A, Rey J, Bouvier Borg G, Gautherot E, Hamel JF, Ifrah N, Lacombe C, Cornillet-Lefebvre P, Delaunay J, Toubert A, Arnoulet C, Vey N, Blaise D, Olive D.

Oncoimmunology. 2017 Mar 24;6(12):e1307491. doi: 10.1080/2162402X.2017.1307491. eCollection 2017.

6.

Interleukin-17A-induced production of acute serum amyloid A by keratinocytes contributes to psoriasis pathogenesis.

Couderc E, Morel F, Levillain P, Buffière-Morgado A, Camus M, Paquier C, Bodet C, Jégou JF, Pohin M, Favot L, Garcia M, Huguier V, Mcheik J, Lacombe C, Yssel H, Guillet G, Bernard FX, Lecron JC.

PLoS One. 2017 Jul 14;12(7):e0181486. doi: 10.1371/journal.pone.0181486. eCollection 2017.

7.

Natural Killer Defective Maturation Is Associated with Adverse Clinical Outcome in Patients with Acute Myeloid Leukemia.

Chretien AS, Fauriat C, Orlanducci F, Galseran C, Rey J, Bouvier Borg G, Gautherot E, Granjeaud S, Hamel-Broza JF, Demerle C, Ifrah N, Lacombe C, Cornillet-Lefebvre P, Delaunay J, Toubert A, Gregori E, Luche H, Malissen M, Arnoulet C, Nunes JA, Vey N, Olive D.

Front Immunol. 2017 May 29;8:573. doi: 10.3389/fimmu.2017.00573. eCollection 2017.

8.

NKp30 expression is a prognostic immune biomarker for stratification of patients with intermediate-risk acute myeloid leukemia.

Chretien AS, Fauriat C, Orlanducci F, Rey J, Borg GB, Gautherot E, Granjeaud S, Demerle C, Hamel JF, Cerwenka A, von Strandmann EP, Ifrah N, Lacombe C, Cornillet-Lefebvre P, Delaunay J, Toubert A, Arnoulet C, Vey N, Olive D.

Oncotarget. 2017 Jul 25;8(30):49548-49563. doi: 10.18632/oncotarget.17747.

9.

High mTORC1 activity drives glycolysis addiction and sensitivity to G6PD inhibition in acute myeloid leukemia cells.

Poulain L, Sujobert P, Zylbersztejn F, Barreau S, Stuani L, Lambert M, Palama TL, Chesnais V, Birsen R, Vergez F, Farge T, Chenevier-Gobeaux C, Fraisse M, Bouillaud F, Debeissat C, Herault O, Récher C, Lacombe C, Fontenay M, Mayeux P, Maciel TT, Portais JC, Sarry JE, Tamburini J, Bouscary D, Chapuis N.

Leukemia. 2017 Nov;31(11):2326-2335. doi: 10.1038/leu.2017.81. Epub 2017 Mar 10.

PMID:
28280275
10.

Comprehensive Proteomic Analysis of Human Erythropoiesis.

Gautier EF, Ducamp S, Leduc M, Salnot V, Guillonneau F, Dussiot M, Hale J, Giarratana MC, Raimbault A, Douay L, Lacombe C, Mohandas N, Verdier F, Zermati Y, Mayeux P.

Cell Rep. 2016 Aug 2;16(5):1470-1484. doi: 10.1016/j.celrep.2016.06.085. Epub 2016 Jul 21.

11.

Comprehensive mutational profiling of core binding factor acute myeloid leukemia.

Duployez N, Marceau-Renaut A, Boissel N, Petit A, Bucci M, Geffroy S, Lapillonne H, Renneville A, Ragu C, Figeac M, Celli-Lebras K, Lacombe C, Micol JB, Abdel-Wahab O, Cornillet P, Ifrah N, Dombret H, Leverger G, Jourdan E, Preudhomme C.

Blood. 2016 May 19;127(20):2451-9. doi: 10.1182/blood-2015-12-688705. Epub 2016 Mar 15.

12.

ECL1i, d(LGTFLKC), a novel, small peptide that specifically inhibits CCL2-dependent migration.

Auvynet C, Baudesson de Chanville C, Hermand P, Dorgham K, Piesse C, Pouchy C, Carlier L, Poupel L, Barthélémy S, Felouzis V, Lacombe C, Sagan S, Chemtob S, Quiniou C, Salomon B, Deterre P, Sennlaub F, Combadière C.

FASEB J. 2016 Jun;30(6):2370-81. doi: 10.1096/fj.201500116. Epub 2016 Mar 15. Erratum in: FASEB J. 2017 Feb;31(2):852.

PMID:
26979087
13.

Pim kinases modulate resistance to FLT3 tyrosine kinase inhibitors in FLT3-ITD acute myeloid leukemia.

Green AS, Maciel TT, Hospital MA, Yin C, Mazed F, Townsend EC, Pilorge S, Lambert M, Paubelle E, Jacquel A, Zylbersztejn F, Decroocq J, Poulain L, Sujobert P, Jacque N, Adam K, So JC, Kosmider O, Auberger P, Hermine O, Weinstock DM, Lacombe C, Mayeux P, Vanasse GJ, Leung AY, Moura IC, Bouscary D, Tamburini J.

Sci Adv. 2015 Sep 18;1(8):e1500221. doi: 10.1126/sciadv.1500221. eCollection 2015 Sep.

14.

Control of Pim2 kinase stability and expression in transformed human haematopoietic cells.

Adam K, Lambert M, Lestang E, Champenois G, Dusanter-Fourt I, Tamburini J, Bouscary D, Lacombe C, Zermati Y, Mayeux P.

Biosci Rep. 2015 Oct 23;35(6). pii: e00274. doi: 10.1042/BSR20150217.

15.

Photos provide information on age, but not kinship, of Andean bear.

Van Horn RC, Zug B, Appleton RD, Velez-Liendo X, Paisley S, LaCombe C.

PeerJ. 2015 Jul 16;3:e1042. doi: 10.7717/peerj.1042. eCollection 2015.

16.

Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibition.

Jacque N, Ronchetti AM, Larrue C, Meunier G, Birsen R, Willems L, Saland E, Decroocq J, Maciel TT, Lambert M, Poulain L, Hospital MA, Sujobert P, Joseph L, Chapuis N, Lacombe C, Moura IC, Demo S, Sarry JE, Recher C, Mayeux P, Tamburini J, Bouscary D.

Blood. 2015 Sep 10;126(11):1346-56. doi: 10.1182/blood-2015-01-621870. Epub 2015 Jul 17.

17.

A mouse model recapitulating human monoclonal heavy chain deposition disease evidences the relevance of proteasome inhibitor therapy.

Bonaud A, Bender S, Touchard G, Lacombe C, Srour N, Delpy L, Oblet C, Druilhe A, Quellard N, Javaugue V, Cogné M, Bridoux F, Sirac C.

Blood. 2015 Aug 6;126(6):757-65. doi: 10.1182/blood-2015-03-630277. Epub 2015 Jun 25.

18.

Hepatocyte growth factor measurement in AL amyloidosis.

Abraham J, Desport E, Rigaud C, Marin B, Bender S, Lacombe C, Moreau S, Yagoubi F, Bordessoule D, Lavergne D, Bridoux F, Jaccard A.

Amyloid. 2015;22(2):112-6. doi: 10.3109/13506129.2015.1014548. Epub 2015 Jun 8.

PMID:
26053104
19.

Co-activation of AMPK and mTORC1 Induces Cytotoxicity in Acute Myeloid Leukemia.

Sujobert P, Poulain L, Paubelle E, Zylbersztejn F, Grenier A, Lambert M, Townsend EC, Brusq JM, Nicodeme E, Decrooqc J, Nepstad I, Green AS, Mondesir J, Hospital MA, Jacque N, Christodoulou A, Desouza TA, Hermine O, Foretz M, Viollet B, Lacombe C, Mayeux P, Weinstock DM, Moura IC, Bouscary D, Tamburini J.

Cell Rep. 2015 Jun 9;11(9):1446-57. doi: 10.1016/j.celrep.2015.04.063. Epub 2015 May 21.

20.

Erythropoiesis and transferrin receptors.

Moura IC, Hermine O, Lacombe C, Mayeux P.

Curr Opin Hematol. 2015 May;22(3):193-8. doi: 10.1097/MOH.0000000000000133. Review.

PMID:
25767952

Supplemental Content

Loading ...
Support Center